

PHARMACY NEWS

TO: MEDICAL and PHARMACY STAFF
FROM: PHARMACY SERVICES

The FHCP Pharmacy and Therapeutic Committee reviewed the following therapeutic classes of drugs at its last meeting held December 11th 2024: Genitourinary Smooth Muscle Relaxants, Pulmonary Smooth Muscle Relaxants Vitamins (B Complex, D Vitamins, Multi-Vitamins, Misc Vitamins), Unclassified Therapeutic Agents, Pulmonary Anti-Inflammatory Agents (non-steroidal), Devices, Bone Density Enhancers, Transplant Agents, Injectables and Biologics, Hematopoietics

2024-25 Formulary Changes

Formulary Additions

Revuforj (revumenib)- Tier 5 PA Medicare only
Itovebi (inavolisib) Tier 5 PA Medicare only
Cobenfy (xanomeline and tropium hydrochloride) Tier 5 PA Medicare only

Formulary Deletions: -

NA

Tier Changes

Biosimilar Humira (Hadlima) is now in Preferred Brand for ACA & Medicare Part D- Previously Specialty Tier

Paxlovid was removed from Commercial and Exchange formularies effective 1-1-2025 at December's P&T Committee meeting. Medicare Members will have access to Paxlovid without a Prior Auth.

This decision was based on a review of Paxlovid utilization as well as characteristics of covid-related hospitalizations in the Commercial/Exchange populations. The review found over 90% of Paxlovid utilization at FHCP in this population was among relatively low risk patients. A Paxlovid course of treatment costs \$1400 and during sporadic outbreaks of the Omicron variant substantial use was experienced by the plan. FHCP has a process to identify and appropriately cover Paxlovid for high-risk patients as described below.

FHCP will proactively identify Commercial/ACA members with the High-risk characteristics and authorize formulary exceptions at the point of sale (FHCP pharmacy) should member become infected, this includes:

- members 65+ year of age
- Currently being treated for malignancy with chemo/immunotherapy
- organ/stem cell transplant
- On highly immunosuppressive therapy
- history of hospitalization for respiratory failure or heart failure
- oxygen therapy

We also have a process for any members not identified above who present to a pharmacy with Paxlovid Rx which can be reviewed promptly for high risk and approved if needed. In addition, if a physician has a patient where prospective Paxlovid authorization is reasonable due to other high-risk characteristics, they can request a formulary exception

THANKS!